Sees FY25 adjusted EBITDA at least $225M. Sees FY25 adjusted net income at least $175M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Adma Biologics options imply 11.5% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, March 03, 2025
- Options Volatility and Implied Earnings Moves This Week, March 03 – March 06, 2025
- Is ADMA a Buy, Before Earnings?
- ADMA Biologics Approves 2025 Executive Compensation Package